Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
BioMarin Pharmaceutical Inc. Stock Forecast NASDAQ:BMRN
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-04-25 | 42.53% | Morgan Stanley | $96.00 $113.00 | Upgrades | Equal-Weight Overweight |
| 2022-04-12 | 21.09% | Morgan Stanley | $90.00 $96.00 | Maintains | Equal-Weight |
| 2022-02-24 | 57.67% | Piper Sandler | $121.00 $125.00 | Maintains | Overweight |
| 2021-11-22 | 32.44% | Credit Suisse | $100.00 $105.00 | Maintains | Outperform |
| 2021-11-22 | 45.06% | SVB Leerink | $112.00 $115.00 | Maintains | Outperform |
| 2021-11-22 | 13.52% | Morgan Stanley | $82.00 $90.00 | Maintains | Equal-Weight |
| 2021-11-22 | - | William Blair | - | Upgrades | Market Perform Outperform |
| 2021-11-15 | 41.27% | SVB Leerink | $108.00 $112.00 | Maintains | Outperform |
| 2021-10-28 | 26.14% | Credit Suisse | $102.00 $100.00 | Maintains | Outperform |
| 2021-09-09 | 21.09% | Stifel | $86.00 $96.00 | Upgrades | Hold Buy |
| 2021-07-29 | 11% | RBC Capital | $87.00 $88.00 | Maintains | Sector Perform |
| 2021-04-19 | 3.43% | Morgan Stanley | $85.00 $82.00 | Maintains | Equal-Weight |
| 2021-03-01 | 14.78% | Canaccord Genuity | $95.00 $91.00 | Maintains | Buy |
| 2021-03-01 | 26.14% | Evercore ISI Group | $90.00 $100.00 | Upgrades | In-Line Outperform |
| 2020-11-06 | 36.23% | SVB Leerink | $113.00 $108.00 | Reiterates | Outperform |
| 2020-09-10 | 57.67% | Truist Securities | $130.00 $125.00 | Maintains | Buy |
| 2020-08-21 | 7.21% | Morgan Stanley | $125.00 $85.00 | Maintains | Equal-Weight |
| 2020-08-20 | - | William Blair | - | Downgrades | Outperform Market Perform |
| 2020-08-20 | 19.83% | Canaccord Genuity | $119.00 $95.00 | Maintains | Buy |
| 2020-08-20 | 16.04% | RBC Capital | $123.00 $92.00 | Downgrades | Outperform Sector Perform |
| 2020-08-20 | 8.48% | Citigroup | $148.00 $86.00 | Downgrades | Buy Neutral |
| 2020-08-19 | 26.14% | Stifel | $127.00 $100.00 | Downgrades | Buy Hold |
| 2020-08-19 | 42.53% | SVB Leerink | $140.00 $113.00 | Maintains | Outperform |
| 2020-08-06 | 36.23% | BMO Capital | $94.00 $108.00 | Maintains | Market Perform |
| 2020-08-05 | 76.59% | SVB Leerink | $130.00 $140.00 | Maintains | Outperform |
| 2020-07-08 | 57.67% | Morgan Stanley | $125.00 | Downgrades | Overweight Equal-Weight |
| 2020-06-18 | 80.37% | SunTrust Robinson Humphrey | $109.00 $143.00 | Maintains | Buy |
| 2020-06-18 | 19.83% | Oppenheimer | $88.00 $95.00 | Maintains | Perform |
| 2020-06-10 | 63.98% | B of A Securities | $120.00 $130.00 | Maintains | Buy |
| 2020-04-30 | 37.49% | SunTrust Robinson Humphrey | $110.00 $109.00 | Maintains | Buy |
| 2020-04-30 | 61.45% | Credit Suisse | $131.00 $128.00 | Maintains | Outperform |
| 2020-03-03 | 57.67% | Morgan Stanley | $120.00 $125.00 | Maintains | Overweight |
| 2020-03-02 | 106.86% | Wedbush | $175.00 $164.00 | Maintains | Outperform |
| 2020-01-28 | 18.57% | BMO Capital | $94.00 | Initiates Coverage On | Market Perform |
| 2020-01-24 | - | RBC Capital | - | Upgrades | Sector Perform Sector Outperform |
| 2019-11-27 | 23.61% | Barclays | $98.00 | Upgrades | Equal-Weight Overweight |
| 2019-11-12 | 38.75% | SunTrust Robinson Humphrey | $110.00 | Initiates Coverage On | Buy |
| 2019-10-30 | 19.83% | Citigroup | $120.00 $95.00 | Maintains | Buy |
| 2019-10-28 | 36.23% | Canaccord Genuity | $117.00 $108.00 | Maintains | Buy |
| 2019-10-25 | 91.73% | Wedbush | $128.00 $152.00 | Maintains | Outperform |
| 2019-10-24 | 8.48% | Barclays | $95.00 $86.00 | Maintains | Equal-Weight |
| 2019-10-24 | -2.88% | Nomura | $93.00 $77.00 | Maintains | Neutral |
| 2019-10-17 | 13.52% | B of A Securities | $90.00 | Reinstates | Buy |
BMRN Stock Trend
The stock is moving within a wide and horizontal trend and further movements within this trend can be expected.
Given the current horizontal trend, you can expect BioMarin Pharmaceutical Inc. stock with a 90% probability to be traded between $76.14 and $88.27 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-23 | $74.84 | $80.80 | $86.76 |
| 2022-05-24 | $74.87 | $80.82 | $86.78 |
| 2022-05-25 | $74.89 | $80.85 | $86.81 |
| 2022-05-26 | $74.92 | $80.87 | $86.83 |
| 2022-05-27 | $74.94 | $80.90 | $86.86 |
| 2022-05-31 | $74.97 | $80.92 | $86.88 |
| 2022-06-01 | $74.99 | $80.95 | $86.91 |
| 2022-06-02 | $75.02 | $80.97 | $86.93 |
| 2022-06-03 | $75.04 | $81.00 | $86.96 |
| 2022-06-06 | $75.07 | $81.02 | $86.98 |
| 2022-06-07 | $75.09 | $81.05 | $87.00 |
| 2022-06-08 | $75.11 | $81.07 | $87.03 |
| 2022-06-09 | $75.14 | $81.10 | $87.05 |
| 2022-06-10 | $75.16 | $81.12 | $87.08 |
| 2022-06-13 | $75.19 | $81.15 | $87.10 |
| 2022-06-14 | $75.21 | $81.17 | $87.13 |
| 2022-06-15 | $75.24 | $81.20 | $87.15 |
| 2022-06-16 | $75.26 | $81.22 | $87.18 |
| 2022-06-17 | $75.29 | $81.25 | $87.20 |
| 2022-06-21 | $75.31 | $81.27 | $87.23 |
| 2022-06-22 | $75.34 | $81.29 | $87.25 |
| 2022-06-23 | $75.36 | $81.32 | $87.28 |
| 2022-06-24 | $75.39 | $81.34 | $87.30 |
| 2022-06-27 | $75.41 | $81.37 | $87.33 |
| 2022-06-28 | $75.44 | $81.39 | $87.35 |
| 2022-06-29 | $75.46 | $81.42 | $87.38 |
| 2022-06-30 | $75.49 | $81.44 | $87.40 |
| 2022-07-01 | $75.51 | $81.47 | $87.43 |
| 2022-07-05 | $75.54 | $81.49 | $87.45 |
| 2022-07-06 | $75.56 | $81.52 | $87.47 |
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary syn... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
